DE69628909T2 - Liposomformulierung von 5-beta steroiden - Google Patents

Liposomformulierung von 5-beta steroiden

Info

Publication number
DE69628909T2
DE69628909T2 DE69628909T DE69628909T DE69628909T2 DE 69628909 T2 DE69628909 T2 DE 69628909T2 DE 69628909 T DE69628909 T DE 69628909T DE 69628909 T DE69628909 T DE 69628909T DE 69628909 T2 DE69628909 T2 DE 69628909T2
Authority
DE
Germany
Prior art keywords
liposome formulation
5beta
dhea
steroid
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69628909T
Other languages
English (en)
Other versions
DE69628909D1 (de
Inventor
Joseph Rubinfeld
L Fineman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Pharmaceuticals Inc
Original Assignee
Supergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supergen Inc filed Critical Supergen Inc
Publication of DE69628909D1 publication Critical patent/DE69628909D1/de
Application granted granted Critical
Publication of DE69628909T2 publication Critical patent/DE69628909T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE69628909T 1995-10-12 1996-09-27 Liposomformulierung von 5-beta steroiden Expired - Fee Related DE69628909T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54208395A 1995-10-12 1995-10-12
PCT/US1996/015507 WO1997013500A2 (en) 1995-10-12 1996-09-27 LIPOSOME FORMULATIONS OF 5β STEROIDS

Publications (2)

Publication Number Publication Date
DE69628909D1 DE69628909D1 (de) 2003-08-07
DE69628909T2 true DE69628909T2 (de) 2003-12-24

Family

ID=24162270

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69628909T Expired - Fee Related DE69628909T2 (de) 1995-10-12 1996-09-27 Liposomformulierung von 5-beta steroiden

Country Status (10)

Country Link
US (1) US6436435B1 (de)
EP (1) EP0801557B1 (de)
JP (1) JPH10508322A (de)
CN (1) CN1173815A (de)
AT (1) ATE243998T1 (de)
CA (1) CA2208215A1 (de)
DE (1) DE69628909T2 (de)
HU (1) HUP9801834A3 (de)
IL (1) IL121070A (de)
WO (1) WO1997013500A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
CA2670236C (en) * 1999-09-30 2012-06-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
FR2799645B1 (fr) 1999-10-13 2004-04-30 Oreal Utilisation de la dhea ou de ses precurseurs ou derives metaboliques comme depigmentant
JP2003512474A (ja) * 1999-10-25 2003-04-02 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 血液細胞欠乏症の治療処置
FR2807323A1 (fr) 2000-04-10 2001-10-12 Oreal Composition, notamment cosmetique, renfermant un steroide et un 2-alkyl alcanol ou un ester
CA2439687A1 (en) * 2001-03-01 2002-09-12 Hollis-Eden Pharmaceuticals, Inc. Use of certain steroids for treatment of blood cell deficiencies
CA2493605A1 (en) * 2001-07-25 2003-02-06 Richard A. Haase Processes and apparatus for the manufacture of polynuclear aluminum compounds and disinfectants, and polynuclear aluminum compounds and disinfectants from such processes and apparatus
FR2827765B1 (fr) * 2001-07-27 2003-09-19 Oreal Composition a base de vesicules lamellaires lipidiques incorporant au moins un compose a base de dhea
FR2827766A1 (fr) * 2001-07-27 2003-01-31 Oreal Composition a base de vesicules lamellaires lipidiques incorporant au moins un compose a base de dhea
US20040034003A1 (en) * 2002-05-01 2004-02-19 Schwartz Arthur G. 7-Hydroxy-16alpha-fluoro-5-androsten-17-ones and 7-hydroxy-16alpha-fluoro-5-androstan-17-ones and derivatives thereof
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8268269B2 (en) 2006-01-24 2012-09-18 Clearvalue Technologies, Inc. Manufacture of water chemistries
US8273770B2 (en) 2007-07-21 2012-09-25 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
ES2558155T3 (es) 2007-10-30 2016-02-02 Indiana University Research And Technology Corporation Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
JP2011504505A (ja) 2007-11-21 2011-02-10 デコード ジェネティクス イーエイチエフ 肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤
JP5501251B2 (ja) 2008-01-11 2014-05-21 アルバニー モレキュラー リサーチ， インコーポレイテッド Ｍｃｈ拮抗薬としての（１−アジノン）置換ピリドインドール類
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
PE20120332A1 (es) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida
BRPI1007350B8 (pt) 2009-01-26 2021-05-25 Israel Institute For Biological Res compostos espiro heterocíclicos bicíclicos
AU2010273732A1 (en) 2009-07-14 2012-02-09 Albany Molecular Research, Inc. 5-HT3 receptor modulators, methods of making, and use thereof
EP2569000B1 (de) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon-superfamilien-peptide mit nuklearhormon-rezeptoraktivität
US9237762B2 (en) 2010-05-24 2016-01-19 Swedish Oat Fiber Ab Aqueous dispersion comprising galactolipids and method for production thereof
MX2012014576A (es) 2010-06-24 2013-02-21 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida.
FR2979239A1 (fr) * 2011-08-25 2013-03-01 Trophos Liposome comprenant au moins un derive de cholesterol
US8859491B2 (en) 2011-11-17 2014-10-14 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
EP3768267A4 (de) 2018-03-20 2022-04-20 Icahn School of Medicine at Mount Sinai Kinaseinhibitorverbindungen und zusammensetzungen und verfahren zur verwendung
CA3124700A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4518595A (en) 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
FR2551758B1 (fr) * 1983-08-16 1986-01-31 Anvar Derives de muramyl-peptides et de steroides ayant des proprietes d'activation des macrophages
US4666898A (en) 1983-12-28 1987-05-19 Jackson Lab. Treatment of obesity, diabetes and other symptoms of hypercorticoidism using etiocholanolones
US4507289A (en) 1983-12-28 1985-03-26 Progenics, Inc. Treatment of diabetes and other symptoms of hypercorticoidism using a synergistic combination of etiocholanolones and estrogen
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
CA1264668C (en) 1984-06-20 1990-01-23 EXTRUSION TECHNIQUES FOR THE PRODUCTION OF LIPOSOMES
EP0231261B1 (de) 1985-07-05 1994-04-06 The Liposome Company, Inc. Multilamellare liposome mit verbesserter einschliessungswirkung
US5041278A (en) 1985-10-15 1991-08-20 The Liposome Company, Inc. Alpha tocopherol-based vesicles
US4861580A (en) 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
DE3626421A1 (de) * 1986-08-05 1988-02-11 Recipe Pharma Vertriebs Gmbh & Peptid, pharmazeutisches mittel und verwendung desselben zur stimulierung der lipolyse
US5006517A (en) 1987-12-01 1991-04-09 Progenics, Inc. Treatment of Prader-Willi syndrome
US5041287A (en) 1989-05-22 1991-08-20 Terry L. Driggers Sprayable composition using acetone solvent
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
AU668934B2 (en) 1992-04-10 1996-05-23 Hisamitsu Pharmaceutical Co., Inc. Liposome composition
WO1994004155A1 (en) * 1992-08-19 1994-03-03 Health Resource Institute, Ltd. Dehydroepiandrosterone therapy for the treatment of eye disorders
US6015576A (en) * 1997-08-29 2000-01-18 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to an antigen

Also Published As

Publication number Publication date
EP0801557B1 (de) 2003-07-02
DE69628909D1 (de) 2003-08-07
IL121070A (en) 2004-06-20
CA2208215A1 (en) 1997-04-17
JPH10508322A (ja) 1998-08-18
WO1997013500A3 (en) 1997-05-29
ATE243998T1 (de) 2003-07-15
EP0801557A2 (de) 1997-10-22
HUP9801834A2 (hu) 1999-02-01
HUP9801834A3 (en) 2000-06-28
WO1997013500A2 (en) 1997-04-17
CN1173815A (zh) 1998-02-18
US6436435B1 (en) 2002-08-20
IL121070A0 (en) 1997-11-20

Similar Documents

Publication Publication Date Title
DE69628909T2 (de) Liposomformulierung von 5-beta steroiden
AU6786696A (en) Hormone patch
NL193616B (nl) Gesubstitueerde androsta-1,4-dieen-3,17-dionen, alsmede farmaceutische preparaten die dergelijke verbindingen bevatten.
PT1090029E (pt) 14,15-ciclopropanoesteroides da serie dos 19-norandrostanos, processo para a sua producao e preparacoes farmaceuticas contendo estes compostos
ATE304845T1 (de) Hautpflaster enthaltend testosteron und gegebenenfalls estrogen
NO20065784L (no) Steroidforbindelser og anvendelse av slike
BR9611533A (pt) Lipopoliamina composição e utilização e processo de preparação de uma lipopoliamina
NL300109I1 (nl) Kristalmodificatie van CDCH, werkwijze voor de bereiding ervan en van farmaceutische preparaten die deze modificaties bevatten.
AU7072596A (en) Method for preparing omega-aminoalkanoic acid derivatives from cycloalkanones
CA2069483A1 (en) Steroid sulphatase inhibitors
AU4101589A (en) Pharmaceutical preparations which can be applied transdermally, containing sterolins and/or spiroketalins
AU5805096A (en) Transdermal therapeutic system (TTS) for the administration of testosterone
PT99435A (pt) Processo para a preparacao de derivados de amino-sulfonil-ureia e de composicoes farmaceuticas que os contem
DK0742214T3 (da) I hjerte-kar-systemet aktive, nye seco-D steroider samt farmaceutiske præparater indeholdende sådanne
WO2001046388A3 (de) Krankhaft veränderte herzmuskelzelle, ihre herstellung und verwendung
ATE183512T1 (de) Kardioaktive 17-hydroxyiminoalkyl- und 17- hydroxyiminomethylalkenyl-steroid-derivate, ein verfahren zu ihrer herstellung und pharmazeutische präparate davon
BR0015531A (pt) Tratamento de lúpus eritematoso sistêmico (sle) com desidroepiandrosterona
AU5278799A (en) Unsaturated 14,15-cyclopropanoandrostanes, method for the production thereof andpharmaceutical preparations containing said compounds
ATE240343T1 (de) Darstellung von esterderivaten von steroiden
EP0172034A3 (de) Mikrobiologischer Abbau von Steroiden
FI946082A0 (fi) Menetelmä steroidisten perasyyliglykosidien valmistamiseksi
LV10902A (lv) Metode holesterina un ta metabolitu izdalisanai no biologiskiem audiem
EP1210874A4 (de) "knockout"-tier für das alpha-tocopherol-transportprotein
GR1001412B (el) Συν?έσεις χρήσιμες δια την ?εραπευτική αγωγή της ξηρότητος του κόλπου.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee